Salud Pública de México (Feb 2022)

Aflatoxin levels and prevalence of TP53 aflatoxin-mutations in hepatocellular carcinomas in Mexico

  • Leonardo S Lino-Silva,
  • Martín Lajous,
  • Marion Brochier,
  • Luis Santiago-Ruiz,
  • Javier Melchor-Ruan,
  • Yi Xie,
  • Mingyi Wang,
  • Dongjing Wu,
  • Herbert Higson,
  • Kristine Jones,
  • Martin Romero-Martínez,
  • Salvador Villalpando,
  • Alejandro Mohar,
  • Joshua W Smith,
  • Christian S Alvarez,
  • Katherine A McGlynn,
  • Michael Dean,
  • John Groopman

DOI
https://doi.org/10.21149/13189
Journal volume & issue
Vol. 64, no. 1
pp. 35 – 40

Abstract

Read online

Objective. To determine the exposure to aflatoxin B1 (AFB1) in southern Mexico and the presence of the aflatoxin signature mutation in hepatocellular carcinoma (HCC) tissue from patients from a cancer referral center. Materials and methods. We estimated the prevalence and distribution of AFB1 in a representative sample of 100 women and men from Chiapas using the National Health and Nutrition Survey 2018-19. We also examined the presence of the aflatoxin signature mutation in codon 249 (R249S), and other relevant mutations of the TP53 gene in HCC tissue blocks from 24 women and 26 men treated in a national cancer referral center. Results. The prevalence of AFB1 in serum samples was 85.5% (95%CI 72.1-93.1) and the median AFB1 was 0.117 pg/μL (IQR, 0.050–0.350). We detected TP53 R249S in three of the 50 HCCs (6.0%) and observed four other G>T transversions potentially induced by AFB1. Conclusion. Our analysis provides evidence that AFB1 may have a relevant role on HCC etiology in Mexico.

Keywords